Pseudomonas aeruginosa bacteremia among immunocompetent and immunocompromised patients: Relation to initialantibiotic therapy and survival

Japanese Journal of Infectious Diseases

Volumn 69, Issue 2, 2016, Pages 91-96

  Migiyama, Yohei ^a,b   Yanagihara, Katsunori ^a   Kaku, Norihito ^a   Harada, Yosuke ^a   Yamada, Koichi ^a   Nagaoka, Kentaro ^a   Morinaga, Yoshitomo ^a   Akamatsu, Norihiko ^a   Matsuda, Junichi ^a   Izumikawa, Koichi ^a   Kohrogi, Hirotsugu ^b   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BACTERIUM ISOLATION; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMIZED PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MICROBIOLOGY; MORTALITY; MULTIVARIATE ANALYSIS; NONHUMAN; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SURVIVAL RATE; ADOLESCENT; AGED; DRUG EFFECTS; IMMUNOCOMPROMISED PATIENT; JAPAN; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SURVIVAL ANALYSIS; UNIVERSITY HOSPITAL; VERY ELDERLY; YOUNG ADULT;

ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOCOMPROMISED HOST; JAPAN; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84961627450     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.JJID.2014.573     Document Type: Article

References (31)

1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848-54
2. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309-17
3. Al-Hasan MN, Wilson JW, Lahr BD, et al. Incidence of Pseudomonas aeruginosa bacteremia: a population-based study. Am J Med. 2008;121:702-8
4. Osmon S, Ward S, Fraser VJ, et al. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest. 2004;125:607-16
5. Morrison AJ, Wenzel RP. Epidemiology of infections due to Pseudomonas aeruginosa. Rev Infect Dis. 1984;6 Suppl 3: S627-42
6. Henderson A, Kelly W, Wright M. Fulminant primary Pseudomonas aeruginosa pneumonia and septicaemia in previously well adults. Intensive Care Med. 1992;18:430-2
7. Hatchette TF, Gupta R, Marrie TJ. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis. 2000;31: 1349-56
8. Huang YC, Lin TY, Wang CH. Community-acquired Pseudomonas aeruginosa sepsis in previously healthy infants and children: analysis of forty-three episodes. Pediatr Infect Dis J. 2002;21: 1049-52
9. Huhulescu S, Simon M, Lubnow M, et al. Fatal Pseudomonas aeruginosa pneumonia in a previously healthy woman was most likely associated with a contaminated hot tub. Infection. 2011;39: 265-9
10. Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol. 2009;7:654-65
11. Feltman H, Schulert G, Khan S, et al. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology. 2001;147:2659-69
12. Berthelot P, Attree I, Pleá siat P, et al. Genotypic and phenotypic analysis of type III secretion system in a cohort of Pseudomonas aeruginosa bacteremia isolates: evidence for a possible association between O serotypes and exo genes. J Infect Dis. 2003;188: 512-8
13. Vincent JL, de Mendonca A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26: 1793-800
14. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-32
15. Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49: 1306-11
16. Schechner V, Nobre V, Kaye KS, et al. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis. 2009;48:580-6
17. Penã a C, Suarez C, Ocampo-Sosa A, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort. Clin Infect Dis. 2013;57:208-16
18. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; 22th informational supplement. Document M100-S22. Wayne, PA: CLSI; 2012
19. Ajayi T, Allmond LR, Sawa T, et al. Single-nucleotide-polymorphism mapping of the Pseudomonas aeruginosa type III secretion toxins for development of a diagnostic multiplex PCR system. J Clin Microbiol. 2003;41:3526-31
20. Wong-Beringer A, Wiener-Kronish J, Lynch S, et al. Comparison of type III secretion system virulence among fluoroquinolonesusceptible and -resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect. 2008;14:330-6
21. Engel J, Eran Y. Subversion of mucosal barrier polarity by Pseudomonas aeruginosa. Front Microbiol. 2011;2:114
22. Gbaguidi-Haore H, Dumartin C, L'Heáriteau F, et al. Antibiotics involved in the occurrence of antibiotic-resistant bacteria: a nationwide multilevel study suggests differences within antibiotic classes. J Antimicrob Chemother. 2013;68:461-70
23. Lodise TP Jr, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother. 2007;51:3510-5
24. Scheetz MH, Hoffman M, Bolon MK, et al. Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol Infect Dis. 2009;64:311-9
25. Parkins MD, Gregson DB, Pitout JD, et al. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection. 2010;38:25-32
26. Leibovici L, Shraga I, Drucker M, et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med. 1998;244:379-86
27. Osih RB, McGregor JC, Rich SE, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2007;51: 839-44
28. Schechner V, Gottesman T, Schwartz O, et al. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy. Diagn Microbiol Infect Dis. 2011;71:38-45
29. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis. 2003;37:745-51
30. Lin MY, Weinstein RA, Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob Agents Chemother. 2008;52: 3188-94
31. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother. 2010;54:1742-8.